Disposition of 6708 shares by Schuth Alexander O. of Denali Therapeutics at 5.28 subject to Rule 16b-3

DNLI Stock  USD 21.26  0.42  2.02%   
Under 67 percent of all Denali Therapeutics' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Denali Therapeutics suggests that a large number of traders are confidant. Denali Therapeutics' investing sentiment shows overall attitude of investors towards Denali Therapeutics.
  
Filed transaction by Denali Therapeutics Officer: Cofo And Secretary. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 6708 stock option (right to buy) at 5.28 of Denali Therapeutics by Schuth Alexander O. on 27th of December 2024. This event was filed by Denali Therapeutics with SEC on 2024-12-27. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Denali Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Denali Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Denali Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Denali Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Denali Therapeutics Maximum Pain Price Across January 17th 2025 Option Contracts

Denali Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Denali Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Denali Therapeutics' options.

Denali Therapeutics Fundamental Analysis

We analyze Denali Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Denali Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Denali Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Denali Therapeutics stock to make a market-neutral strategy. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics with similar companies.

Peers

Denali Therapeutics Related Equities

TVTXTravere Therapeutics   8.90   
0%
100.0%
DSGNDesign Therapeutics   7.94   
0%
89.0%
HOWLWerewolf Therapeutics   7.69   
0%
86.0%
RNAAvidity Biosciences   7.22   
0%
81.0%
SWTXSpringWorks Therapeutics   5.85   
0%
65.0%
LEGNLegend Biotech   3.02   
0%
33.0%
BDTXBlack Diamond   2.80   
0%
31.0%
IKNAIkena Oncology   2.42   
0%
27.0%
STOKStoke Therapeutics   1.95   
0%
21.0%
PCVXVaxcyte   1.76   
0%
19.0%
ASNDAscendis Pharma   1.74   
0%
19.0%
FDMT4D Molecular   1.72   
0%
19.0%
BPMCBlueprint Medicines   1.32   
0%
14.0%
APLSApellis Pharmaceuticals   0.90   
0%
10.0%
GLUEMonte Rosa   0.84   
0%
9.0%
AKROAkero Therapeutics   0.57   
0%
6.0%
BGNEBeiGene   0.49   
0%
5.0%
RVMDRevolution Medicines   0.27   
0%
3.0%
DAWNDay One   0.94   
10.0%
0%

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Directory
Find actively traded commodities issued by global exchanges